Vogenx (NASDAQ:VOGX – Get Free Report) announced its earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, Zacks reports.
Vogenx Stock Up 2.2%
Shares of NASDAQ VOGX traded up $0.74 during midday trading on Thursday, reaching $34.13. 209,756 shares of the company were exchanged, compared to its average volume of 196,990. Vogenx has a one year low of $12.95 and a one year high of $36.00.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the stock. JonesTrading assumed coverage on shares of Vogenx in a research report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price target on the stock. WBB Securities started coverage on shares of Vogenx in a research report on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 price objective for the company. Finally, Wall Street Zen upgraded Vogenx to a “hold” rating in a research note on Saturday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. Based on data from MarketBeat.com, Vogenx has a consensus rating of “Strong Buy” and an average price target of $48.50.
About Vogenx
Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.
The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.
Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.
Further Reading
- Five stocks we like better than Vogenx
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.
